Mark McPartland | executive |
Shawn Singh | executive |
Cynthia Anderson | executive |
Julian Pino | analyst |
Lin Tsai | analyst |
Joshua Prince | executive |
Tim Lugo | analyst |
Greetings, and welcome to Vistagen Therapeutics Fiscal Year 2024 Third Quarter Financial Results and Corporate Update. [Operator Instructions].
As a reminder, this conference is being recorded. It is now my pleasure to introduce Mark McPartland, Senior Vice President, Investor Relations of Vistagen. Thank you.